Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

Lucilla Parnetti, Davide Chiasserini, Gianni Bellomo, David Giannandrea, Claudia de Carlo, Mohamed M. Qureshi, Mustafa T. Ardah, Shiji Varghese, Laura Bonanni, Barbara Borroni, Nicola Tambasco, Paolo Eusebi, Aroldo Rossi, Marco Onofrj, Alessandro Padovani, Paolo Calabresi, Omar El-Agnaf

Research output: Contribution to journalArticle

Abstract

Although alpha-synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, Aβ1-42, total tau, phosphorylated tau, and α-synuclein can improve discrimination of Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia. Aβ1-42, total tau, phosphorylated tau, and α-synuclein were measured in a series of patients with Parkinson's disease (n = 38), dementia with Lewy bodies (n = 32), Alzheimer's disease (n = 48), frontotemporal dementia (n = 31), and age-matched control patients with other neurological diseases (n = 32). Mean α-synuclein levels in cerebrospinal fluid were significantly lower in the pathological groups than in cognitively healthy subjects. An inverse correlation of α-synuclein with total tau (r = -0.196, P <.01) was observed. In the group of patients with Parkinson's disease, Aβ1-42, total tau, and phosphorylated tau values were similar to controls, whereas total tau/α-synuclein and phosphorylated tau/α-synuclein ratios showed the lowest values. Cerebrospinal fluid α-synuclein alone did not provide relevant information for Parkinson's disease diagnosis, showing low specificity (area under the curve, 0.662; sensitivity, 94%; specificity, 25%). Instead, a better performance was obtained with the total tau/α-syn ratio (area under the curve, 0.765; sensitivity, 89%; specificity, 61%). Combined determination of α-synuclein and classical biomarkers in cerebrospinal fluid shows differential patterns in neurodegenerative disorders. In particular, total tau/α-synuclein and phosphorylated tau/α-synuclein ratios can contribute to the discrimination of Parkinson's disease.

Original languageEnglish
Pages (from-to)1428-1435
Number of pages8
JournalMovement Disorders
Volume26
Issue number8
DOIs
Publication statusPublished - Jul 2011

Keywords

  • Alpha-synuclein
  • Alzheimer's disease
  • Cerebrospinal fluid biomarkers
  • Dementia with Lewy bodies
  • Frontotemporal dementia
  • Parkinson's disease
  • Phosphorylated tau
  • Total tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias'. Together they form a unique fingerprint.

  • Cite this

    Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., de Carlo, C., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., Tambasco, N., Eusebi, P., Rossi, A., Onofrj, M., Padovani, A., Calabresi, P., & El-Agnaf, O. (2011). Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Movement Disorders, 26(8), 1428-1435. https://doi.org/10.1002/mds.23670